Skip to main content
. 2020 Jul 28;9(8):2422. doi: 10.3390/jcm9082422

Table 2.

Risk of PD in patients with IBD according to KM treatment.

Monotherapy Integrative Therapy
n Events Person-Year Incidence a n Events Person-Year Incidence Crude HR (95% CI) Adjusted b HR (95% CI)
All 411 25 2968 8.4 1405 55 10890 5.1 0.60 (0.37–0.96) 0.56 (0.34–0.92)
Sex
Male 242 13 1718 7.6 526 19 3980 4.8 0.63 (0.31–1.28) 0.57 (0.28–1.17)
Female 169 12 1249 9.6 879 36 6910 5.2 0.54 (0.28–1.04) 0.58 (0.29–1.14)
Age
<65 197 8 1607 5.0 664 20 5489 3.6 0.73 (0.32–1.66) 0.77 (0.33–1.82)
≥65 214 17 1361 12.5 741 35 5392 6.5 0.52 (0.29–0.92) 0.51 (0.28–0.94)
Medication use
0 112 7 806 8.7 273 14 2084 6.7 0.77 (0.31–1.92) 0.79 (0.30–2.08)
1 299 18 2162 8.3 1132 41 8607 4.7 0.56 (0.32–0.97) 0.54 (0.30–0.96)

a Per 1000 person-years; b Model adjusted for sex, age, alcohol, cardiovascular, chronic kidney, chronic obstructive pulmonary disease, dementia, depression, diabetes mellitus, hyperlipdemial, hypertension, medication use, hospitalization medical use, outpatient medical use, and number of hospitals visited. HR: hazard ratio.